跳至主要内容
临床试验/NL-OMON51834
NL-OMON51834尚未招募不适用

ongitudinal variation of blood based biomarkers in moderate-to-severe atopic dermatitis patients, a prospective cohort study - BIOMAD study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 260 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Adult patients with moderate-to-severe atopic dermatitis
  • - An intention to start cyclosporine A, dupilumab, tralokinumab, oral
  • JAK-inhibitor (abrocitinib or upadacitinib) treatment according to the NVDV
  • - Documented recent history (last 6 months) of eligibility for treatment with
  • immunosuppressants, biologicals and JAK-inhibitors.

排除标准

  • - Children and adolescents (<18 years)
  • - men and women planning pregnancy during study, pregnant women and
  • breastfeeding women
  • - Patients with other inflammatory skin diseases, autoimmune diseases, or other
  • inflammatory diseases will be excluded (eg. psoriasis, diabetes mellitus,
  • inflammatory bowel
  • disease, rheumatoid arthrtitis).

研究者

相似试验